

Special Issue

Health Economics of Vaccines 2.0

Message from the Guest Editors

The health economic analysis of vaccines is increasing in importance. In many jurisdictions, cost effectiveness plays an important role in the final decision to include a vaccine into the National Immunization Program. The UK's Joint Committee of Vaccination and Immunization may serve as an example here. It is often argued that cost effectiveness for vaccines typically differs from that for curative drugs with specificities in the areas of broader economic impacts, indirect effects, spillovers, timing of benefits, and evidence requirements. This Special Issue aims to provide an overview of these aspects from both theoretical and practical (illustrations) angles. Building on our previous Special Issue on health economics, this Special Issue on "Health Economics 2.0" shall expand on these issues and aims to include—in addition to other infections—the first analyses on the cost effectiveness of COVID-19 vaccines.

Guest Editors

Prof. Dr. Maarten J. Postma

Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands

Prof. Dr. Cornelis Boersma

Unit of Global Health, Department of Health Sciences, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands

Deadline for manuscript submissions

closed (31 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/80590

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).